{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:51:40Z","timestamp":1788274300597,"version":"build-2803163510"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"3","funder":[{"DOI":"10.13039\/501100005062","name":"Fujirebio Europe, Gent, Belgium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2023-0314_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Numerous prognostic models have been proposed for ovarian cancer, extending from single serological factors to complex gene-expression signatures. Nonetheless, these models have not been routinely translated into clinical practice. We constructed a robust and readily calculable model for predicting surgical outcome and prognosis of ovarian cancer patients by exploiting commonly available clinico-pathological factors and three selected serum parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0314_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum CA125, human epididymis protein 4 (HE4) and mesothelin (MSL) were quantified by Lumipulse<jats:sup>\u00ae<\/jats:sup> G chemiluminescent enzyme immunoassay (Fujirebio) in a total of 342 serum samples from 190 ovarian cancer patients, including 152 paired pre- and post-operative samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0314_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Detection of pre-operative HE4 and CA125 was the optimal marker combination for blood-based prediction of surgical outcome (AUC=0.86). We constructed a prognostic model, computed by serum levels of pre-operative CA125, post-operative HE4, post-operative MSL and surgical outcome. Prognostic performance of our model was superior to any of these parameters alone and was independent from <jats:italic>BRCA1\/2<\/jats:italic> mutational status. We subsequently transformed our model into a prognostic risk index, stratifying patients as \u201clower risk\u201d or \u201chigher risk\u201d. In \u201chigher risk\u201d patients, relapse or death was predicted with an AUC of 0.89 and they had a significantly shorter progression free survival (HR: 9.74; 95\u202f% CI: 5.95\u201315.93; p&lt;0.0001) and overall survival (HR: 5.62; 95\u202f% CI: 3.16\u20139.99; p&lt;0.0001) compared to \u201clower risk\u201d patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2023-0314_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We present a robust predictive\/prognostic model for ovarian cancer, which could readily be implemented into routine diagnostics in order to identify ovarian cancer patients at high risk of recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2023-0314","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:01:58Z","timestamp":1696978918000},"page":"530-539","source":"Crossref","is-referenced-by-count":8,"title":["A predictive and prognostic model for surgical outcome and prognosis in ovarian cancer computed by clinico-pathological and serological parameters (CA125, HE4, mesothelin)"],"prefix":"10.1515","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7696-9043","authenticated-orcid":false,"given":"Daniel Martin","family":"Klotz","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"National Center for Tumour Diseases (NCT) , Dresden , Germany"},{"name":"German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Link","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"National Center for Tumour Diseases (NCT) , Dresden , Germany"},{"name":"German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"National Center for Tumour Diseases (NCT) , Dresden , Germany"},{"name":"German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Dominik","family":"Kuhlmann","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"National Center for Tumour Diseases (NCT) , Dresden , Germany"},{"name":"German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Faculty of Medicine and University Hospital Carl Gustav Carus , Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Helmholtz-Zentrum Dresden-Rossendorf (HZDR) , Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"2024012313272694806_j_cclm-2023-0314_ref_001","doi-asserted-by":"crossref","unstructured":"Torre, LA, Trabert, B, DeSantis, CE, Miller, KD, Samimi, G, Runowicz, CD, et al.. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","DOI":"10.3322\/caac.21456"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_002","doi-asserted-by":"crossref","unstructured":"du Bois, A, Quinn, M, Thigpen, T, Vermorken, J, Avall-Lundqvist, E, Bookman, M, et al.. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(8 Suppl):viii7\u201312. https:\/\/doi.org\/10.1093\/annonc\/mdi961.","DOI":"10.1093\/annonc\/mdi961"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_003","doi-asserted-by":"crossref","unstructured":"Karam, A, Ledermann, JA, Kim, JW, Sehouli, J, Lu, K, Gourley, C, et al.. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017;28:711\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx011.","DOI":"10.1093\/annonc\/mdx011"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_004","doi-asserted-by":"crossref","unstructured":"Stuart, GC, Kitchener, H, Bacon, M, duBois, A, Friedlander, M, Ledermann, J, et al.. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011;21:750\u20135. https:\/\/doi.org\/10.1097\/igc.0b013e31821b2568.","DOI":"10.1097\/IGC.0b013e31821b2568"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_005","doi-asserted-by":"crossref","unstructured":"Ray-Coquard, I, Pautier, P, Pignata, S, Perol, D, Gonzalez-Martin, A, Berger, R, et al.. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381:2416\u201328. https:\/\/doi.org\/10.1056\/nejmoa1911361.","DOI":"10.1056\/NEJMoa1911361"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_006","doi-asserted-by":"crossref","unstructured":"Gonzalez-Martin, A, Pothuri, B, Vergote, I, DePont Christensen, R, Graybill, W, Mirza, MR, et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/nejmoa1910962.","DOI":"10.1056\/NEJMoa1910962"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_007","doi-asserted-by":"crossref","unstructured":"Waldron, L, Haibe-Kains, B, Culhane, AC, Riester, M, Ding, J, Wang, XV, et al.. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 2014;106:dju049. https:\/\/doi.org\/10.1093\/jnci\/dju049.","DOI":"10.1093\/jnci\/dju049"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_008","doi-asserted-by":"crossref","unstructured":"Tothill, RW, Tinker, AV, George, J, Brown, R, Fox, SB, Lade, S, et al.. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-0196.","DOI":"10.1158\/1078-0432.CCR-08-0196"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_009","doi-asserted-by":"crossref","unstructured":"Laios, A, Katsenou, A, Tan, YS, Johnson, R, Otify, M, Kaufmann, A, et al.. Feature selection is critical for 2-year prognosis in advanced stage high grade serous ovarian cancer by using machine learning. Cancer Control 2021;28:10732748211044678. https:\/\/doi.org\/10.1177\/10732748211044678.","DOI":"10.1177\/10732748211044678"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_010","doi-asserted-by":"crossref","unstructured":"Wimberger, P, Wehling, M, Lehmann, N, Kimmig, R, Schmalfeldt, B, Burges, A, et al.. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010;17:1642\u20138. https:\/\/doi.org\/10.1245\/s10434-010-0964-9.","DOI":"10.1245\/s10434-010-0964-9"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_011","doi-asserted-by":"crossref","unstructured":"Menon, U, Gentry-Maharaj, A, Burnell, M, Singh, N, Ryan, A, Karpinskyj, C, et al.. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397:2182\u201393. https:\/\/doi.org\/10.1016\/s0140-6736(21)00731-5.","DOI":"10.1016\/S0140-6736(21)00731-5"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_012","doi-asserted-by":"crossref","unstructured":"Hertlein, L, Stieber, P, Kirschenhofer, A, Krocker, K, Nagel, D, Lenhard, M, et al.. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012;50:2181\u20138. https:\/\/doi.org\/10.1515\/cclm-2012-0097.","DOI":"10.1515\/cclm-2012-0097"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_013","doi-asserted-by":"crossref","unstructured":"Sonoda, G, Palazzo, J, du Manoir, S, Godwin, AK, Feder, M, Yakushiji, M, et al.. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas. Genes Chromosomes Cancer 1997;20:320\u20138. https:\/\/doi.org\/10.1002\/(sici)1098-2264(199712)20:4<320::aid-gcc2>3.0.co;2-3.","DOI":"10.1002\/(SICI)1098-2264(199712)20:4<320::AID-GCC2>3.3.CO;2-S"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_014","doi-asserted-by":"crossref","unstructured":"Galgano, MT, Hampton, GM, Frierson, HFJr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847\u201353. https:\/\/doi.org\/10.1038\/modpathol.3800612.","DOI":"10.1038\/modpathol.3800612"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_015","doi-asserted-by":"crossref","unstructured":"Drapkin, R, von Horsten, HH, Lin, Y, Mok, SC, Crum, CP, Welch, WR, et al.. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-04-3924.","DOI":"10.1158\/0008-5472.CAN-04-3924"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_016","doi-asserted-by":"crossref","unstructured":"Bast, RCJr, Badgwell, D, Lu, Z, Marquez, R, Rosen, D, Liu, J, et al.. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(3 Suppl):274\u201381. https:\/\/doi.org\/10.1111\/j.1525-1438.2005.00441.x.","DOI":"10.1111\/j.1525-1438.2005.00441.x"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_017","doi-asserted-by":"crossref","unstructured":"Rump, A, Morikawa, Y, Tanaka, M, Minami, S, Umesaki, N, Takeuchi, M, et al.. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190\u20138. https:\/\/doi.org\/10.1074\/jbc.m312372200.","DOI":"10.1074\/jbc.M312372200"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_018","doi-asserted-by":"crossref","unstructured":"Gubbels, JA, Belisle, J, Onda, M, Rancourt, C, Migneault, M, Ho, M, et al.. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50. https:\/\/doi.org\/10.1186\/1476-4598-5-50.","DOI":"10.1186\/1476-4598-5-50"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_019","doi-asserted-by":"crossref","unstructured":"Scholler, N, Garvik, B, Hayden-Ledbetter, M, Kline, T, Urban, N. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Cancer Lett 2007;247:130\u20136. https:\/\/doi.org\/10.1016\/j.canlet.2006.03.029.","DOI":"10.1016\/j.canlet.2006.03.029"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_020","doi-asserted-by":"crossref","unstructured":"Bruney, L, Conley, KC, Moss, NM, Liu, Y, Stack, MS. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16\/CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium. Biol Chem 2014;395:1221\u201331. https:\/\/doi.org\/10.1515\/hsz-2014-0155.","DOI":"10.1515\/hsz-2014-0155"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_021","doi-asserted-by":"crossref","unstructured":"Giordano, G, Ferioli, E, Tafuni, A. The role of mesothelin expression in serous ovarian carcinoma: impacts on diagnosis, prognosis, and therapeutic targets. Cancers (Basel) 2022;14:2283. https:\/\/doi.org\/10.3390\/cancers14092283.","DOI":"10.3390\/cancers14092283"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_022","doi-asserted-by":"crossref","unstructured":"Liu, X, Chan, A, Tai, CH, Andresson, T, Pastan, I. Multiple proteases are involved in mesothelin shedding by cancer cells. Commun Biol 2020;3:728. https:\/\/doi.org\/10.1038\/s42003-020-01464-5.","DOI":"10.1038\/s42003-020-01464-5"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_023","doi-asserted-by":"crossref","unstructured":"FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2009;105:3\u20134. https:\/\/doi.org\/10.1016\/j.ijgo.2008.12.015.","DOI":"10.1016\/j.ijgo.2008.12.015"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_024","doi-asserted-by":"crossref","unstructured":"Prat, J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_025","doi-asserted-by":"crossref","unstructured":"Link, T, Passek, S, Wimberger, P, Frank, K, Vassileva, YD, Kramer, M, et al.. Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer. Int J Cancer 2020;146:2608\u201318. https:\/\/doi.org\/10.1002\/ijc.32676.","DOI":"10.1002\/ijc.32676"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_026","doi-asserted-by":"crossref","unstructured":"Klotz, DM, Link, T, Wimberger, P, Kuhlmann, JD. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer. Mol Oncol 2021;15:3626\u201338. https:\/\/doi.org\/10.1002\/1878-0261.12949.","DOI":"10.1002\/1878-0261.12949"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_028","doi-asserted-by":"crossref","unstructured":"Feng, LY, Liao, SB, Li, L. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study. J Ovarian Res 2020;13:17. https:\/\/doi.org\/10.1186\/s13048-020-0614-1.","DOI":"10.1186\/s13048-020-0614-1"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_029","doi-asserted-by":"crossref","unstructured":"Braicu, EI, Fotopoulou, C, Van Gorp, T, Richter, R, Chekerov, R, Hall, C, et al.. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol 2013;128:245\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2012.11.023.","DOI":"10.1016\/j.ygyno.2012.11.023"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_030","unstructured":"Huang, CY, Cheng, WF, Lee, CN, Su, YN, Chien, SC, Tzeng, YL, et al.. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res 2006;26:4721\u20138."},{"key":"2024012313272694806_j_cclm-2023-0314_ref_031","doi-asserted-by":"crossref","unstructured":"Shi, M, Mu, Y, Zhang, H, Liu, M, Wan, J, Qin, X, et al.. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: a meta-analysis. Medicine (Baltim) 2018;97:e11505. https:\/\/doi.org\/10.1097\/md.0000000000011505.","DOI":"10.1097\/MD.0000000000011505"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_032","doi-asserted-by":"crossref","unstructured":"Wang, Y, Li, BX, Li, X. Identification and validation of angiogenesis-related gene expression for predicting prognosis in patients with ovarian cancer. Front Oncol 2021;11:783666. https:\/\/doi.org\/10.3389\/fonc.2021.783666.","DOI":"10.3389\/fonc.2021.783666"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_033","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609\u201315. https:\/\/doi.org\/10.1038\/nature10166.","DOI":"10.1038\/nature10166"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_034","doi-asserted-by":"crossref","unstructured":"Konecny, GE, Wang, C, Hamidi, H, Winterhoff, B, Kalli, KR, Dering, J, et al.. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014;106:dju249. https:\/\/doi.org\/10.1093\/jnci\/dju249.","DOI":"10.1093\/jnci\/dju249"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_035","doi-asserted-by":"crossref","unstructured":"Millstein, J, Budden, T, Goode, EL, Anglesio, MS, Talhouk, A, Intermaggio, MP, et al.. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol 2020;31:1240\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.019.","DOI":"10.1016\/j.annonc.2020.05.019"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_036","doi-asserted-by":"crossref","unstructured":"Hellstrom, I, Hellstrom, KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and\/or each other. Adv Exp Med Biol 2008;622:15\u201321. https:\/\/doi.org\/10.1007\/978-0-387-68969-2_2.","DOI":"10.1007\/978-0-387-68969-2_2"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_037","doi-asserted-by":"crossref","unstructured":"Hellstrom, I, Hellstrom, KE. fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Expert Opin Med Diagn 2011;5:227\u201340. https:\/\/doi.org\/10.1517\/17530059.2011.559459.","DOI":"10.1517\/17530059.2011.559459"},{"key":"2024012313272694806_j_cclm-2023-0314_ref_038","unstructured":"Abdel-Azeez, HA, Labib, HA, Sharaf, SM, Refai, AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010;11:111\u20136."},{"key":"2024012313272694806_j_cclm-2023-0314_ref_039","doi-asserted-by":"crossref","unstructured":"Moore, K, Colombo, N, Scambia, G, Kim, BG, Oaknin, A, Friedlander, M, et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495\u2013505. https:\/\/doi.org\/10.1056\/nejmoa1810858.","DOI":"10.1056\/NEJMoa1810858"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0314\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T13:30:53Z","timestamp":1706016653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2023-0314\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,13]]},"published-print":{"date-parts":[[2024,2,26]]}},"alternative-id":["10.1515\/cclm-2023-0314"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2023-0314","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}